Daniel Rauch

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +11

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial

Miklos Pless, Roger Stupp, Hans-Beat Ris et al. · The Lancet · 2015 · 390 citations

Medicine, Oncology, Radiation Oncology +13

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

Rafael Rosell, Urania Dafni, Enriqueta Felip et al. · The Lancet Respiratory Medicine · 2017 · 183 citations

Medicine, Oncology, Pharmacology +12

Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)

Dieter Koeberle, Jean‐François Dufour, Gyula Demeter et al. · Annals of Oncology · 2016 · 139 citations · Full text

Medicine, Oncology, Pharmacology +15